Patents Examined by Sagar Patel
  • 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
    Patent number: 11306066
    Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicaments. The disclosure further relates to inhibitors of IRAP and their use in the treatment or prevention of Alzheimer's disease and the treatment and prevention of memory and cognitive disorders.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: April 19, 2022
    Assignee: Monash University
    Inventors: Siew Yeen Chai, Philip Thompson, Simon Mountford, Michael W. Parker
  • Combination therapy using ascochlorin derivative
    Patent number: 11298358
    Abstract: An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly a cancer. The present invention provides a combination therapy using a compound presented by formula (I), a pharmaceutically acceptable salt or a solvate thereof with an immune checkpoint inhibitor.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 12, 2022
    Inventor: Tatsuo Hoshino
  • Cyclic di-nucleotide compounds and methods of use
    Patent number: 11299512
    Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: April 12, 2022
    Assignees: IMMUNESENSOR THERAPEUTICS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Boyu Zhong, Heping Shi, Yuanwei Dai, Qi Wei, Chuo Chen, Zhijian Chen, Lijun Sun
  • Compositions and methods for treating cancer
    Patent number: 11286241
    Abstract: This invention is directed to compositions and methods for treating cancer in a patient.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: March 29, 2022
    Assignee: GLAX LLC
    Inventors: Rakesh K Srivastava, Sharmila Shankar, Sushant Kumar Shrivastava, Prabhash Nath Tripathi, Pavan Srivastava
  • Organic electroluminescent compound and organic electroluminescent device comprising the same
    Patent number: 11289662
    Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having low driving voltage and/or high luminous efficiency can be provided. At the same time or selectively, an organic electroluminescent device having excellent lifespan characteristic and/or formable of a thin film of excellent quality can be provided.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: March 29, 2022
    Inventor: Jeong-Eun Yang
  • Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
    Patent number: 11241439
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: February 8, 2022
    Assignee: Celgene Corporation
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • Bicyclic compounds and methods of use
    Patent number: 11236105
    Abstract: The present invention provides compounds that modulate protein function, specifically phosphodiesterase 4 (PDE4). The invention provides methods of treating, ameliorating, and/or preventing diseases, disorders, and conditions associated with PDE4. Compositions, including in combination with other inflammatory mediators, are also provided.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: February 1, 2022
    Assignee: BioTheryX, Inc.
    Inventors: Robert Sullivan, Paul E. Erdman, Eduardo Torres, Leah Fung, Kyle W. H. Chan, Frank Mercurio
  • 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same
    Patent number: 11230539
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by absormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: January 25, 2022
    Assignee: CrystalGenomics, Inc.
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Photoprotective compositions containing -derived compounds and/or chemical analogs thereof
    Patent number: 11220491
    Abstract: The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and/or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 11, 2022
    Assignee: Versicolor Technologies, LLC
    Inventors: Michael Einziger, Ann Marie Simpson
  • Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
    Patent number: 11192887
    Abstract: Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: December 7, 2021
    Assignee: Bantam Pharmaceutical, LLC
    Inventors: M. Arshad Siddiqui, Stephane Ciblat, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Nicolas Bruneau-Latour, Gerald W. Shipps, Alan B. Cooper, Vibha Oza, Matthew J. Kostura, Michael Luther, Jedd Levine
  • Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
    Patent number: 11186566
    Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: November 30, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Timothy Alcacio, Minson Baek, Peter Grootenhuis, Sara Sabina Hadida Ruah, Robert M. Hughes, Ali Keshavarz-Shokri, Rachel McAuley-Aoki, Jason McCartney, Mark Thomas Miller, Fredrick Van Goor, Beili Zhang, Corey Anderson, Thomas Cleveland, Bryan A. Frieman, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Vito Melillo, Fabrice Jean Denis Pierre, Andreas P. Termin, Johnny Uy, Jinglan Zhou, Alexander Russell Abela, Brett Bradley Busch, Prasuna Paraselli
  • Sequestering compositions and materials
    Patent number: 11174277
    Abstract: The present disclosure relates to a composition that includes a sequestering material capable of binding a target material, where the sequestering material includes a first component that includes at least one of a functional group, a molecule, an oligomer, or a polymer, and the target material includes at least one of an element, a chemical, and/or a compound. In some embodiments of the present disclosure, the element may include at least one element from at least one of Rows 4, 5, 6, and 7 of the Periodic Table and/or an inner transition metal.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: November 16, 2021
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: Kai Zhu, Tao Xu
  • Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization
    Patent number: 11124479
    Abstract: The invention relates to compounds and pharmaceutical compositions capable of treating amyloid diseases and other diseases characterized by oligomerization and/or fibrillation of amyloidogenic peptides such as islet amyloid polypeptide (IAPP).
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: September 21, 2021
    Assignee: NEW YORK UNIVERSITY
    Inventors: Andrew D. Hamilton, Sunil Kumar
  • Benzimidazole compounds as c-Kit inhibitors
    Patent number: 11117883
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: September 14, 2021
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Yun Zhang, Xiaotian Zhu
  • Method for the industrial production of 2-halo- 4,6-dialkoxy-l,3,5-triazines and their use in the presence of amines
    Patent number: 11111221
    Abstract: A method for stabilization of collagen matrices and of condensation of natural and synthetic polymers that uses 2-halo-4, 6-dialkoxy-1, 3, 5-triazines in the presence of one or more amines as activating agents for reactions of crosslinking, condensation, grafting, and curing of collagen matrices, cellulose, modified celluloses, polysaccharides, acid unsaturated polymers, and chiral and non-chiral amines, etc. Forming an integral part of the present invention is also the method for production on an industrial scale of 2-halo-4, 6-dialkoxy-1, 3, 5-triazines.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 7, 2021
    Assignee: CROSSING SRL
    Inventor: Valentina Beghetto
  • Hydroxide-catalyzed formation of silicon-oxygen bonds by dehydrogenative coupling of hydrosilanes and alcohols
    Patent number: 11104693
    Abstract: The present disclosure is directed to methods for dehydrogenatively coupled hydrosilanes and alcohols, the methods comprising contacting an organic substrate having at least one organic alcohol moiety with a mixture of at least one hydrosilane and sodium and/or potassium hydroxide, the contacting resulting in the formation of a dehydrogenatively coupled silyl ether. The disclosure further described associated compositions and methods of using the formed products.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 31, 2021
    Assignee: California Institute of Technology
    Inventors: Anton Toutov, Kerry Betz, Andrew M. Romine, Robert H. Grubbs
  • Use of 2,4-dihalo-6-substituted-1,3,5-triazines and derivative thereof as condensation, cross-linking, tanning, grafting and curing agents
    Patent number: 11104767
    Abstract: Use of 2,4-dihalo-6-substituted-1,3,5-triazines as condensing, cross-linking, tanning, grafting, curing agents for the production of amides, esters, thioesters, and stabilized collagen and leather, CMC (carboxymethyl cellulose), synthetic and natural polymers. The process enables to obtain non-toxic and totally free of heavy metals products characterized by Tg values between 80° C. and 100° C.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 31, 2021
    Assignee: CROSSING SRL
    Inventors: Valentina Beghetto, Lodovico Agostinis
  • Heterocyclic compounds as RSV inhibitors
    Patent number: 11091501
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Jianming Yu, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Thomas P. Blaisdell, Brian C. Shook, Yat Sun Or
  • Antibacterial agents against D,D- and L,D-transpeptidases
    Patent number: 11084833
    Abstract: Antibacterial agents against D,D- and L,D-transpeptidases are disclosed. Pharmaceutical compositions and methods of using the same also are disclosed.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: August 10, 2021
    Assignee: The Johns Hopkins University
    Inventors: Craig A. Townsend, Evan Lloyd
  • Ammoxidation reactor control
    Patent number: 11078156
    Abstract: A process is provided for control of an ammoxidation reactor. More specifically, the process includes controlling an amount of oxygen added to the reactor, steam temperature and linear velocity to minimize reactor temperature deviations.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 3, 2021
    Assignee: INEOS EUROPE AG
    Inventors: Manoj Shrikant Shouche, Timothy Robert McDonel, Jay Robert Couch